Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Titel:
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Auteur:
Beer, Tomasz M Hotte, Sebastien J Saad, Fred Alekseev, Boris Matveev, Vsevolod Fléchon, Aude Gravis, Gwenaelle Joly, Florence Chi, Kim N Malik, Zafar Blumenstein, Brent Stewart, Patricia S Jacobs, Cindy A Fizazi, Karim